Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. (NYSE: A) is a global company in analytical and clinical laboratory technologies, and its news flow reflects activity across life sciences, diagnostics, and applied markets. Company announcements highlight how Agilent’s instruments, software, services, and expertise are used to help customers bring great science to life, as well as how it manages its financial performance and corporate governance.
On this page, readers can follow Agilent news related to earnings results, product introductions, regulatory-focused solutions, capital allocation, and investor events. Recent releases include quarterly and full-year financial results, with details on revenue, net income, and segment performance for the Life Sciences and Diagnostics Markets Group, the Agilent CrossLab Group, and the Applied Markets Group. These updates often include management commentary on business conditions and outlook.
Agilent’s news also covers product and technology developments. For example, the company has announced 21 CFR Part 11 compliance software for the xCELLigence RTCA eSight system, designed to support use in GMP-regulated manufacturing and quality control environments by adding secure user authentication, electronic signatures, and audit trails. Another announcement introduced Agilent Altura Ultra Inert HPLC Columns, described as high performance liquid chromatography columns suited for biotherapeutics applications such as peptide GLP-1 and oligonucleotide therapeutic development and quality control.
Investors and analysts can also find updates on capital markets activities, such as cash dividend declarations on Agilent’s common stock, and notices of participation in healthcare and investor conferences. Governance-related news, including leadership transitions and executive appointments, is communicated through press releases and related SEC filings. Bookmarking this page allows users to review Agilent’s ongoing communications about its operations, technologies, financial performance, and corporate developments in one place.
Agilent Technologies (NYSE: A) supports research by IIT Bombay and QIMR Berghofer on a new method to distinguish between severe and mild COVID-19 patients. Using the Agilent Cary 630 FTIR Spectrometer, researchers analyzed blood plasma from 160 patients and developed a classification algorithm. The method showed 69.2% specificity and 94.1% sensitivity in predicting severe cases. This advancement aims to aid healthcare workers in prioritizing resources efficiently amid ongoing COVID-19 challenges. Agilent's commitment to infectious disease research is underscored by this collaboration.
Agilent Technologies reported $1.59 billion in revenue for Q3 2021, marking a 26% year-over-year increase. GAAP net income was $264 million or 86 cents per share, up from $199 million or 64 cents in Q3 2020. Non-GAAP net income rose to $337 million or $1.10 per share, compared to $243 million or 78 cents a year ago. The company raised its revenue outlook for FY 2021 to between $6.29 billion and $6.32 billion and expects Q4 revenue of $1.63 billion to $1.66 billion.
Agilent Technologies Inc. (NYSE: A) has achieved Great Place to Work certification, based on feedback from 5,679 U.S. employees. An impressive 86% reported Agilent as a great workplace, significantly higher than the 59% benchmark for typical U.S. companies. The recognition underscores Agilent's commitment to fairness, equity, and integrity, reflected in high scores for treatment of employees across various demographics. Additionally, Agilent is recognized globally, having won similar awards in China, Germany, India, and Spain.
Agilent Technologies (NYSE: A) has established in-country manufacturing for its SureSelect portfolio at its Hangzhou, China facility. This move aims to enhance delivery turnaround times for next-generation sequencing assays, allowing faster development and optimization of custom panels. The new manufacturing site will maintain the same high-quality standards as U.S. counterparts, enabling quicker customer access to assay technology. Agilent's investment reflects its commitment to growth opportunities in the China market and reinforces its genomics capabilities.
Agilent Technologies (NYSE: A) announced the 2021 Early Career Professor Award recipient, Dr. Jason H. Yang, from Rutgers New Jersey Medical School. This award focuses on innovative solutions for managing immunological responses to diseases. Dr. Yang's research combines high-throughput experimentation with machine learning to develop engineered macrophages as therapies for infections, autoimmunity, and cancer. The award supports his cutting-edge research and strengthens Agilent's commitment to advancing scientific innovation.
Agilent Technologies Inc. (NYSE: A) announced a study published in the journal Lung Cancer, highlighting the effectiveness of next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) for detecting ALK fusions in lung cancer patients. Conducted in collaboration with Resolution Bioscience and Memorial Sloan Kettering Cancer Center, the study emphasizes the non-invasive nature and clinical utility of this method. Findings suggest that ctDNA testing can monitor resistance mechanisms in patients undergoing targeted therapy, supporting precision oncology.
Summary not available.
Agilent Technologies Inc. (NYSE: A) will announce its third-quarter fiscal year 2021 financial results on Tuesday, August 17, after market close. A live webcast for the investor conference call will occur the same day at 1:30 p.m. Pacific time, accessible via the Investor Relations section of Agilent's website. The company reported revenues of $5.34 billion in fiscal year 2020 and employs 16,400 individuals globally. The webcast will be available for 90 days following the event.
Agilent Technologies (NYSE: A) has expanded the labeling of its PD-L1 IHC 22C3 pharmDx assay for use in patients with non-small cell lung cancer (NSCLC) in the European Union. The assay helps identify NSCLC patients with Tumor Proportion Score (TPS) ≥ 50% for treatment with Libtayo® (cemiplimab). Lung cancer is the leading cause of cancer death, with NSCLC accounting for about 85% of cases. This initiative underscores Agilent's commitment to developing diagnostics for targeted cancer therapy.
Agilent Technologies Inc. (NYSE: A) has launched a new eMethod for PFAS Analysis in Water using liquid chromatography and mass spectrometry. This solution enables rapid testing for over 100 PFAS compounds in drinking and surface water, significantly reducing analysis time from weeks to hours. The method aligns with evolving global regulations, helping environmental customers update their testing protocols. The comprehensive analytical workflow includes sample preparation, acquisition, and quantitation methods, ensuring compliance with current and future regulations.